

Updates and Controversies in COVID-19

W. Cameron McGuire, MD, MPH

PCCSM Fellow – PGY4

UC San Diego Health

The Publication Soap Opera...

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Mandeep R. Mehra, M.D., Sapan S. Desai, M.D., Ph.D., SreyRam Kuy, M.D., M.H.S., Timothy D. Henry, M.D., and Amit N. Patel, M.D.

May 1, 2020

THE LANCET
Available online 30 May 2020
In Press, Corrected Proof



Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

May 22, 2020

Department of Error
Department of Error

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

The Lancet Editors

Published: June 03, 2020 • DOI: [https://doi.org/10.1016/S0140-6736\(20\)31290-3](https://doi.org/10.1016/S0140-6736(20)31290-3) • Check for updates

Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.
N Engl J Med. DOI: 10.1056/NEJMoa2007621.

June 4, 2020

Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Mandeep R Mehra • Frank Ruschitzka • Amit N Patel

Published: June 05, 2020 • DOI: [https://doi.org/10.1016/S0140-6736\(20\)31324-6](https://doi.org/10.1016/S0140-6736(20)31324-6) • Check for updates

Hydroxychloroquine is still not a miracle drug...

- Despite these high profile retractions, there is still no evidence of benefit in large hydroxychloroquine trials

ORIGINAL ARTICLE

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

David R. Boulware, M.D., M.P.H., Matthew F. Pullen, M.D., Ananta S. Bangdiwala, M.S., Katelyn A. Pastick, B.Sc., Sarah M. Lofgren, M.D., Elizabeth C. Okafor, B.Sc., Caleb P. Skipper, M.D., Alanna A. Nascene, B.A., Melanie R. Nicol, Pharm.D., Ph.D., Mahsa Abassi, D.O., M.P.H., Nicole W. Engen, M.S., Matthew P. Cheng, M.D., [et al.](#)

JAMA | **Original Investigation**

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Eli S. Rosenberg, PhD; Elizabeth M. Dufort, MD; Tomoko Udo, PhD; Larissa A. Wilberschied, MS; Jessica Kumar, DO; James Tesoriero, PhD; Patti Weinberg, PA; James Kirkwood, MPH; Alison Muse, MPH; Jack DeHovitz, MD; Debra S. Blog, MD; Brad Hutton, MPH; David R. Holtgrave, PhD; Howard A. Zucker, MD

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

Joseph Magagnoli, Siddharth Narendran, Felipe Pereira, Tammy Cummings, James W Hardin, S Scott Sutton, Jayakrishna Ambati

doi: <https://doi.org/10.1101/2020.04.16.20065920>

Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial

Philippe GAUTRET, Jean Christophe LAGIER, Philippe PAROLA, Van Thuan HOANG, Line MEDDED, Morgan MAILHE, Barbara DOUDIER, Johan COURJON, Valerie GIORDANENGO, Vera ESTEVES VIEIRA, Herve TISSOT DUPONT, Stephane HONORE, Philippe COLSON, Eric CHABRIERE, Bernard LA SCOLA, Jean Marc ROLAIN, Philippe BROUQUI, Didier RAOULT Sr.

Convalescent Plasma was underwhelming for critically ill patients...

JAMA | **Original Investigation**

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li, MD, PhD; Wei Zhang, MD; Yu Hu, MD, PhD; Xunliang Tong, MD, PhD; Shangen Zheng, MD; Juntao Yang, PhD; Yujie Kong, MD; Lili Ren, PhD; Qing Wei, MD; Heng Mei, MD, PhD; Caiying Hu, MD; Cuihua Tao, MD; Ru Yang, MD; Jue Wang, MD; Yongpei Yu, PhD; Yong Guo, PhD; Xiaoxiong Wu, MD; Zhihua Xu, MD; Li Zeng, MD; Nian Xiong, MD; Lifeng Chen, MD; Juan Wang, MD; Ning Man, MD; Yu Liu, PhD; Haixia Xu, MD; E. Deng, MS; Xuejun Zhang, MS; Chenyue Li, MD; Conghui Wang, PhD; Shisheng Su, PhD; Linqi Zhang, PhD; Jianwei Wang, PhD; Yanyun Wu, MD, PhD; Zhong Liu, MD, PhD

But the trial has some promising limitations...

Asymptomatic Carriers are Real and Common...

Annals of Internal Medicine

Prevalence of Asymptomatic SARS-CoV-2 Infection

A Narrative Review

Daniel P. Oran, AM, and Eric J. Topol, MD

Asymptomatic persons seem to account for approximately 40% to 45% of SARS-CoV-2 infections, and they can transmit the virus to others for an extended period, perhaps longer than 14 days.

Masks are recommended...

Advice on the use of masks in the context of COVID-19

Interim guidance

5 June 2020



World Health
Organization

And beneficial...

Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

*Derek K Chu, Elie A Akl, Stephanie Duda, Karla Solo, Sally Yaacoub, Holger J Schünemann, on behalf of the COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors**